MEMBERS

Lab Block Level 3, Box 231

Addenbrooke’s Hospital

Cambridge, CB2 0QQ, UK

Telephone: +44 (0)1223 762655

E-Mail: sdt36@cam.ac.uk

Medical University of Vienna

Währinger Gürtel,18-20, A-1090 Vienna, Austria

Vienna, Austria Tel:+43-1-40400-63900

Mobile: 0043-664-9697337

E-Mail: olaf.merkel@meduniwien.ac.at

www.meduniwien.ac.at

Währinger Gürtel 18-20

1090 Vienna, Austria

Phone: +43 1 40400 63890

E-Mail: gerda.egger@meduniwien.ac.at

Lukas Kenner is board certified pathologist and an internationally acknowledged expert in comparative pathology. His research interest is the exploration of molecular mechanisms in neoplastic disease, their functional relevance for tumor progression and potential for clinical i8mprovements through diagnostic and prognostic measures. He has generated several transgenic mouse models for investigating the roles of AP-1 and PDGFRB in NPM-ALK transgenic mice.

Währingerstrasse 13A

phone: +43 1 427764111

E-Mail: Lukas.kenner@lbicr.lbg.ac.at

Prof. Sarka Pospisilova is head of the research center of Molecular Medicine in CEITEC, MU and also works in the department of Internal Medicine – Hematology and Oncology in the University Hospital Brno. She coordinates national and international research projects in leukaemia and lymphoma and is a member of the board of the European Research Initiative on CLL (ERIC) within the European Leukaemia Net. Her research group studies the genomic background of ALK-related malignancies (with application of NGS and array technologies) and the role of the p53 pathway and microRNAs in these tumours.

Assoc. Prof. Andrea Janíková is a head of Lymphoma working group of the Hematology and Oncology Department, University Hospital Brno. She is responsible for diagnostic and clinical management of lymphoma patients, clinical data and samples logistics. She is a board member of Czech Lymphoma Study Group, which is the national organization unifying all universities and covering more than 85% of all newly diagnosed systemic lymphomas in the Czech Republic.

Publication Link (AJ)

Kamenice 753/5

Brno – Bohunice 625 00, Czech Republic

Phone: +420532234622

E-Mail: sarka.pospisilova@ceitec.muni.cz
E-Mail: janikova.andrea@fnbrno.cz

Publication Link (LQF)

University Hospital Tuebingen

Eberhard-Karls-University

Liebermeisterstrasse 8

72076 Tuebingen, Germany

Phone: 0049/7071-29-82266

E-Mail: falko.fend@med.uni-tuebingen.de
E-Mail: leticia.quintanilla-fend@med.uni-tuebingen.de

Prof. Carlo Gambacorti-Passerini is a leading physician in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas.

20900 Monza, Italy

Phone: 0039 0392339553

E-Mail: carlo.gambacorti@unimib.it

Team 7: RNA biology in hematological cancers

Oncopole de Toulouse, Entrée C,

2 avenue Hubert Curien

CS53717

31037 TOULOUSE Cedex 1 – FRANCE

phone: 0033-5-82-74-15-75

E-Mail: sylvie.giuriato@inserm.fr

Charité University Medical School

Campus Virchow-Klinikum

13353 Berlin, Germany

Phone: 0049 30 94 06 – 28 63

E-Mail: stephan.mathas@charite.de

Roberto Chiarle has wide expertise in cellular biology, immunology, and molecular biology. He holds clinical qualifications for haematopathology and is currently the recipient of a double appointment as Full Professor and clinical physician at the University of Torino and as Associate Professor at Harvard Medical School. RC is a pioneer in the field of ALK-related lymphoma having generated one of the first mouse models of ALK-induced ALCL. His research aims at therapeutic targeting of ALK by means of specific inhibitors, drugs and immunotherapy. His objectives are therefore to improve our understanding of the molecular mechanisms of

• ALK-driven transformation with in vitro and in vivo models
• Mechanisms of chromosomal translocation formation in different tissues
• Cancer Immunotherapy of ALK-driven cancers

University of Torino

Via Santena, 7 – 10126 Torino, ITALY

Phone: +39 011.633.6861

E-Mail: roberto.chiarle@unito.it

Dept of Pediatric Hematology and Oncology

Justus-Liebig-University

Feulgenstr. 12

35392 Giessen

Phone: +49- (0) 641-985-43462 or -43400

E-Mail: wilhelm.woessmann@paediat.med.uni-giessen.de
E-Mail: Christine.Damm-Welk@paediat.med.uni-giessen.de

39, rue Camille Desmoulins

94 800 Villejuif

Phone: + 33 (0)1 42 11 50 05

E-Mail: Laurence.brugieres@gustaveroussy.fr
E-Mail: Veronique.MINARD@gustaveroussy.fr

Ruth Palmer has been working with ALK in the fruitfly Drosophila melanogaster since 1996. The laboratory is investigating ALK signal transduction with an interest in its role in developmental processes employing Drosophila melanogaster and mouse model systems. Our aim is to understand the importance and function of the ALK receptor tyrosine kinase during both normal and pathological developmental process.

Publication Link (RP)

413 90, Göteborg

Phone: +46 31 7863815

E-Mail: bengt.hallberg@gu.se
E-Mail: ruth.palmer@gu.se

Publication Link (LI)

University Medical Center Freiburg

Dept. of Hematology, Oncology and Stem Cell Transplantation

Hugstetter Str. 55

79106 Freiburg, Germany

Tel: 0761-270-34060

Fax: 0761-270-32060

E-Mail: Justus.Duyster@uniklinik-freiburg.de
E-Mail: lena.illert@uniklinik-freiburg.de